Medicare publishes initial guidance on drug price negotiations (NYSE:MRK)

March 17, 2023

in Stocks

Reading Time: 2 mins read

Big pharma held steady on Thursday after the Centers for Medicare & Medicaid Services (CMS) issued initial guidance on the Medicare drug price negotiation program that will go into effect in 2026.

Support authors and subscribe to content

This is premium stuff. Subscribe to read the entire article.

Gain access to all our Premium contents.
More than 100+ articles.

Subscribe Now

Buy Article

Unlock this article and gain permanent access to read it.

Unlock Now

Medicare publishes initial guidance on drug price negotiations (NYSE:MRK)

Related Articles

The Biggest Stock Market Risk After Trump Win Is China Trade War Move

Why David Einhorn Is Buying CNH, a Cheap Stock ‘No One Cares About’

5 Charts Showing the Immense Market Impact of Trump’s Presidential Win: BofA

Oil Outlook: US Production Boom, Weak China Demand to Lead to Oversupply in 2025

Stock Market Today: Tech Leads Sell-Off As Rate-Cut Odds Fall on Powell

Inflation Outlook: 4 Signs of Re-Inflation Investors Should Watch Out for

Oppenheimer Predicts up to 740% Rally for These 2 ‘Strong Buy’ Stocks

8 Tax Loopholes to Reduce or Avoid Capital Gains Taxes

5 Signs Economy Is Heading Toward Recession — Putting Stocks at Risk

Navigate Site

Welcome Back!

Retrieve your password

Are you sure want to unlock this post?

Are you sure want to cancel subscription?

Medicare publishes initial guidance on drug price negotiations (NYSE:MRK)

Support authors and subscribe to content

Subscribe

Buy Article

Related Articles

Navigate Site

Follow Us

Welcome Back!

Retrieve your password

Are you sure want to unlock this post?

Are you sure want to cancel subscription?